z-logo
Premium
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial
Author(s) -
Kei Anastazia,
Liberopoulos Evangelos,
Tellis Kostantinos,
Rizzo Manfredi,
Elisaf Moses,
Tselepis Alexandros
Publication year - 2013
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12095
Subject(s) - fenofibrate , rosuvastatin , dyslipidemia , medicine , statin , apolipoprotein b , rosuvastatin calcium , randomized controlled trial , endocrinology , lipid profile , pharmacology , cholesterol , gastroenterology , obesity
Background The effects of different hypolipidemic treatment strategies on emerging atherosclerosis risk factors remain unknown. Materials and methods This is a prespecified analysis of a prospective, randomized, open‐label, blinded end point ( PROBE ) study ( ClinicalTrials.gov identifier: NCT01010516). Patients ( n  = 100) with mixed dyslipidaemia on a standard statin dose who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add‐on‐statin extended release nicotinic acid ( ER ‐ NA )/laropiprant ( LRPT ) or to add‐on‐statin micronized fenofibrate for a total of 3 months. Results Following 3 months of treatment, low‐density lipoprotein ( LDL ) particle size increased equally in all groups. Similarly, all treatments were associated with comparable small dense LDL cholesterol reduction. Apolipoprotein B levels decreased by 15%, 7% and 4% in the rosuvastatin, add‐on ER ‐ NA / LRPT and add‐on fenofibrate group, respectively ( P  < 0·01 for all compared with baseline, P  < 0·01 for all comparisons between groups). Only add‐on ER ‐ NA / LRPT was associated with lipoprotein (a) reduction (26%, P  < 0·01 compared with baseline). Rosuvastatin monotherapy and add‐on ER ‐ NA / LRPT groups were associated with 56% and 24% reduction in high‐sensitivity C ‐reactive protein levels (hs CRP ), respectively ( P  < 0·01 compared with baseline), while add‐on fenofibrate was not associated with changes in hs CRP concentration. Lipoprotein‐associated phospholipase A 2 (Lp‐ PLA 2 ) activity decreased similarly in both rosuvastatin and add‐on fenofibrate groups, while add‐on ER ‐ NA / LRPT was associated with a more pronounced Lp‐ PLA 2 activity reduction. ER ‐ NA / LRPT was associated with more side effects compared with rosuvastatin and add‐on fenofibrate. Conclusions Add‐on ER ‐ NA / LRPT followed by switch to the highest dose rosuvastatin were associated with more pronounced beneficial modifications in emerging cardiovascular risk factors compared with add‐on fenofibrate in patients with mixed dyslipidaemia.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here